Active substance : montelukast
Form : sachets of granules
Dosage : One sachet of granules contains 4 mg of montelukast
Packaging : Box with 14 sachets
Target : children from 6 months to 5 years of age
Alukon is indicated in the treatment of asthma as add-on therapy in patients 6 months to 5 years of age with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom ‘as-needed’ short acting beta-agonists provide inadequate clinical control of asthma.
Alukon can also be an alternative to low-dose inhaled corticoids in patients 2 to 5 years of age with mild persistent asthma with no recent history of severe asthma attacks requiring oral corticoid therapy, and who have demonstrated inability to adhere to inhaled corticoid therapy.
Alukon is also indicated in the prophylaxis of asthma from 2 years of age and older in which the predominant component is exercise-induced bronchoconstriction.
Patients of 6 months to 5 years
One (1) sachet of 4 mg granules per day, to be taken in the evening.
At least 1 hour before or 2 hours after food.
There is no need to adjust the dosage in this age group.
Prescription drugs. Please contact your doctor.
Dear valued partners, customers and Dafra representatives,
It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo (https://www.dafrapharma-vet.com/). In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.
Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.
We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.
We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.
As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.
Thank you for your continued support and trust in our company.
Dafra Pharma
